

Standard Medicare Part D* checklist



This checklist can help you receive Sensipar® (cinacalcet) at the lowest possible cost. You can use this checklist if you:

- Have Standard Medicare Part D* prescription insurance
- Have been prescribed Sensipar®

Step completed	Step description
<input type="checkbox"/>	Your health care professional will submit a Prior Authorization form, if required
<input type="checkbox"/>	Discuss the Standard Medicare Part D* benefit with your health care professional <ul style="list-style-type: none">• Use the Medicare Part D calculator at AmgenAssist.com to learn about Standard Medicare Part D* coverage• Standard Medicare Part D* includes the “donut hole” coverage gap
<input type="checkbox"/>	Discuss available grants from an independent co-pay foundation with your health care professional <ul style="list-style-type: none">• Use the Medicare Part D calculator at AmgenAssist.com to see how an independent co-pay foundation may be able to help you lower the cost of Sensipar® if you qualify
<input type="checkbox"/>	Apply for a grant from an independent co-pay foundation <ul style="list-style-type: none">• Talk to your health care professional to see if you qualify• Provide the necessary form(s) to your health care professional
<input type="checkbox"/>	Fill your Sensipar® prescription
<input type="checkbox"/>	Tell your health care professional that you received your Sensipar®

If you have any problems filling your Sensipar® (cinacalcet) prescription, discuss it with the dialysis staff at your next session.

* Standard Medicare Part D includes those who have purchased a Part D prescription plan but who have sufficient assets or income that disqualify them from receiving Medicaid or the low-income subsidy (LIS).

Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Sensipar® is indicated for the treatment of severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy.

Sensipar®
(cinacalcet) Tablets
30mg-60mg-90mg

Indication

Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Sensipar® is indicated for the treatment of severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy.

Important Safety Information

Sensipar® treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).

Sensipar® lowers serum calcium; therefore, it is important that patients are carefully monitored for the occurrence of hypocalcemia.

Significant reductions in calcium may lower the threshold for seizures. Secondary hyperparathyroidism (HPT) patients, particularly those with a history of seizure disorder, should be carefully monitored for the occurrence of low serum calcium or symptoms of hypocalcemia.

In Sensipar® postmarketing use, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia were reported in patients with impaired cardiac function. The causal relationship to Sensipar® therapy could not be completely excluded and may be mediated by reductions in serum calcium levels.

Adynamic bone disease may develop if intact parathyroid hormone (iPTH) levels are suppressed below 100 pg/mL.

Patients with moderate to severe hepatic impairment should be monitored throughout treatment with Sensipar®, as cinacalcet exposure assessed by area under the curve (AUC) was higher than in patients with normal hepatic function.

Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar®. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.

The most commonly reported side effects were nausea, vomiting, and diarrhea.